10-K: CV Sciences Faces Going Concern Amid Sales Decline, Regulatory Hurdles

CV Sciences reported a 12.2% drop in net product sales for 2025 and a 'substantial doubt' about its ability to continue as a going concern, despite improved gross margins and reduced operating losses.

Summary

• Net product sales decreased by $1.9 million, or 12.2%, to $13.8 million in 2025 compared to $15.7 million in 2024, primarily due to a 12.6% lower sales volume.
• Gross profit declined by $0.4 million, or 5.8%, to $6.8 million in 2025, but gross margin improved to 49.0% from 45.6% in 2024.
• Operating loss significantly improved to $(0.47) million in 2025 from $(2.19) million in 2024.
• Net loss narrowed to $(0.96) million in 2025 from $(2.39) million in 2024.
• Adjusted EBITDA improved to $(0.30) million in 2025 from $(0.77) million in 2024.
• Negative cash flows from operations were $(0.4) million in 2025, an improvement from $(0.9) million in 2024.
• The company had an accumulated deficit of $87.9 million and cash of $0.3 million as of December 31, 2025.
• Management and auditors expressed 'substantial doubt' about the company's ability to continue as a going concern.
• The November 2025 Appropriations Act will prohibit the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container effective November 12, 2026, which could materially impact the business.
• The company repaid the Streeterville Note prior to maturity in 2025, recognizing a gain of $37,500.
• In March 2026, existing promissory notes were amended to include a conversion feature into common stock at $0.06 per share, with the aggregate principal amount increasing by 20% to $2.256 million.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with significant concern. While operational efficiencies improved gross margins and reduced losses, the substantial decline in core revenue and the explicit 'going concern' warning, coupled with severe impending regulatory restrictions on its primary product category, indicate a highly precarious financial position and uncertain future viability.

Positives

• Gross margin improved to 49.0% in 2025 from 45.6% in 2024, driven by lower shipping, fulfillment, and production costs.
• Cost of goods sold decreased by 17.6% in 2025 compared to 2024.
• Operating loss significantly narrowed to $(0.47) million in 2025 from $(2.19) million in 2024.
• Net loss decreased to $(0.96) million in 2025 from $(2.39) million in 2024.
• Adjusted EBITDA improved to $(0.30) million in 2025 from $(0.77) million in 2024.
• Selling, general and administrative expenses decreased by 17.5% to $7.6 million in 2025.
• Successfully repaid the Streeterville Note prior to its maturity, resulting in a gain on extinguishment of $37,500.
• 39% of net revenue for 2025 came from 39 new products launched since January 1, 2023, indicating successful product innovation.
• Acquired Cultured Foods (European plant-based protein) in December 2023 and Elevated Softgels (softgel/tincture manufacturer) in May 2024, diversifying product offerings and capabilities.
• Recognized a $0.5 million benefit from the reversal of accrued payroll taxes due to the expiration of the statute of limitations.

Negatives

• Net product sales decreased by 12.2% in 2025, primarily due to a 12.6% decline in units sold.
• The company reported negative cash flows from operations of $0.4 million in 2025.
• An accumulated deficit of $87.9 million as of December 31, 2025, and limited cash resources of $0.3 million.
• Management and the independent registered public accounting firm expressed 'substantial doubt' about the company's ability to continue as a going concern.
• Increased interest expense, net, to $0.517 million in 2025 from $0.212 million in 2024.
• The drug development program (CVSI-007) remains dormant due to significant capital requirements, leading to curtailed patent protection support.
• The November 2025 Appropriations Act, effective November 12, 2026, will severely restrict the sale of most current hemp-derived products by changing the THC measurement standard and imposing a 0.4mg total THC cap per container.
• A California emergency order, extended through March 25, 2026, bans the sale of certain hemp products, negatively impacting operating results.
• Experienced temporary out-of-stock situations for some key products due to manufacturing constraints.
• Warrants for 10,750,000 shares with a weighted average exercise price of $0.0991 expired unexercised during 2025.

Risks

• Intense competition in the fragmented CBD-based consumer product industry, including from illicit market operators.
• Legal and regulatory risks associated with the industries in which the company operates, particularly the evolving and inconsistent federal and state regulations for hemp-derived CBD products.
• The November 2025 Appropriations Act's new definition of hemp and THC limits, effective November 12, 2026, could materially adversely impact the company's ability to sell the majority of its current product lines.
• Uncertainty regarding FDA approval of CBD as an additive to products under the FDCA, as the FDA has stated a new regulatory pathway is needed.
• Restrictive state regulations, such as California's emergency order banning certain hemp products, could continue to negatively impact revenues.
• The company's ability to raise additional capital to finance operations and growth initiatives is uncertain, which could adversely affect its future operations and viability.
• General economic and business conditions, including rising inflation and high interest rates, could adversely impact financial performance.
• Volatility of operating results, financial condition, and stock price.
• Ability to attract or retain qualified senior management personnel.
• Adverse effects from natural disasters, public health crises, political crises, war, negative global climate patterns, or other catastrophic events.
• Cybersecurity threats could disrupt IT networks, lead to data breaches, damage reputation, and expose the company to liability.
• Potential impact of U.S. and foreign government trade policies, including tariffs on imports from China, on sales, gross margin, and profitability.

Future Outlook

Management anticipates continued dependence on additional investment capital to fund operations and growth initiatives. The company plans to innovate new products, build brand awareness, and evaluate further acquisitions. However, the company is evaluating the potential material adverse impact of the November 2025 Appropriations Act on its product portfolio and supply chain, which takes effect November 12, 2026. Inventory levels are expected to normalize in 2026 following temporary out-of-stock situations.

Management Comments

• "We intend to continue building an efficient and cost effective consumer products platform."
• "We intend to continue to evaluate inbound and outbound merger, sale, acquisition or other opportunities for the Company."
• "Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund our operations and growth initiatives."
• "Management implemented, and continues to make and implement, strategic cost reductions, including reductions in employee headcount, vendor spending, and the delaying of certain expenses related to our drug development activities."
• "We believe that our future success will depend, in part, on our ability to continue to attract, hire, and retain qualified personnel."

Industry Context

StockSavvy.ai notes that CV Sciences operates in a highly competitive and fragmented CBD-based consumer product industry, characterized by a lack of clear federal regulatory framework and a patchwork of state regulations. The company's diversification into plant-based foods in Europe positions it in a growing market, though it faces competition from larger players in manufacturing. The broader industry is experiencing consolidation during economic downturns, which could impact smaller players like CV Sciences.

Comparison to Industry Standards

• The CBD market is highly competitive with numerous companies, including publicly-traded peers like Charlotte's Web Holdings Inc., cbdMD, Inc., and Medterra CBD, Inc.
• In the European plant-based food market, CV Sciences' Cultured Foods brand offers shelf-stable products, differentiating it from most competitors who offer refrigerated products.
• As a manufacturer of encapsulated softgels, Elevated Softgels offers unique capabilities by handling both small and large minimum order quantity (MOQ) production runs, contrasting with larger manufacturing competitors that typically require larger MOQs.
• In cannabinoid therapeutics, the company's dormant CVSI-007 program faces competition from companies like GW Pharmaceuticals plc (plant-based CBD) and Harmony Biosciences Holdings, Inc. (synthetic CBD).

Corporate Governance

Legal Proceedings

• The Ruth Complaint, a stockholder derivative suit alleging breach of fiduciary duty and gross mismanagement, was settled in principle in January 2022, with final approval granted on May 15, 2023. The company agreed to corporate governance reforms, and attorney's fees of approximately $250,000 were fully paid as of December 31, 2025.
• The Colette Complaint, a putative class action alleging product labeling violations of the Food, Drug, and Cosmetic Act, remains stayed. The court's order to stay the proceeding until FDA rulemaking on CBD ingestible products is complete has not been lifted, despite the FDA's announcement in January 2023 that it does not intend to pursue such rulemaking.
• The company initiated an arbitration with JAMS against its former legal counsel, Procopio, Cory, Hargreaves & Savitch LLP, on February 12, 2025. The company seeks damages for reliance on Procopio's advice regarding tax withholding for former CEO Mona's RSU settlement. The hearing is scheduled to begin on October 12, 2026.

Related Party Transactions

• The company derecognized a contingent liability of $0.5 million related to employer and employee Medicare portion of FICA taxes associated with the RSU release to former CEO Mona in 2019, as the statute of limitations expired on April 15, 2025.

Stakeholder Impact

• Shareholders face significant risk due to the 'substantial doubt' about the company's ability to continue as a going concern, potential dilution from the conversion feature of amended notes, and the adverse impact of regulatory changes on core product lines.
• Employees experienced headcount reductions in 2025 as part of strategic cost-cutting measures.
• Customers may experience changes in product availability and formulation due to impending regulatory restrictions on hemp-derived products and temporary out-of-stock situations.
• Creditors (institutional investors) hold secured promissory notes, with obligations guaranteed by the company's subsidiaries, and now have the option to convert debt into common stock.

Next Steps

• Evaluate and pursue additional acquisitions to further diversify product offerings.
• Assess and, if necessary, modify product formulations, labeling, and related compliance measures in response to the November 2025 Appropriations Act by November 13, 2026.
• Work towards increasing revenue and operating cash flows to meet future liquidity requirements.
• Position the company to raise additional funds through capital markets, issuance of debt, and/or securing lines of credit.
• Continue strategic cost reductions, including employee headcount and vendor spending.
• Monitor the outcome of legislative efforts in Congress regarding hemp-derived cannabinoid products.
• Participate in the arbitration hearing with Procopio, Cory, Hargreaves & Savitch LLP, scheduled to begin on October 12, 2026.
• Expect inventory levels to normalize in 2026 following temporary out-of-stock situations.

Key Dates

Recommendation

The 'substantial doubt about the Company's ability to continue as a going concern' is a paramount concern for any investor. This fundamental viability issue, combined with a 12.2% decline in net product sales and severe impending regulatory restrictions (November 2025 Appropriations Act) that threaten the majority of its core hemp-derived product lines, creates an extremely high-risk profile. While some operational metrics improved, these are overshadowed by the existential threats. A seasoned investor would likely view the company as facing significant headwinds that could lead to further value erosion or even insolvency, making a 'strong sell' recommendation appropriate.

Keywords

Hemp-derived CBD, Nutraceuticals, Plant-based foods, SEC filing, 10-K, CV Sciences, CVSI, Cannabinoids, Regulatory risk, Going concern, Financial performance, Acquisitions, Capital raise, OTC:QB